Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.


Journal

NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166

Informations de publication

Date de publication:
16 Jul 2021
Historique:
received: 16 12 2020
accepted: 08 06 2021
entrez: 17 7 2021
pubmed: 18 7 2021
medline: 18 7 2021
Statut: epublish

Résumé

Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic Lymphoma Kinase (ALK)-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) are relevant tools to identify additional resistance mechanisms and can be sequenced at the single-cell level. Here, we provide in-depth investigation of copy number alteration (CNA) heterogeneity in phenotypically characterized CTCs at resistance to ALK-TKIs in ALK-positive non-small cell lung cancer. Single CTC isolation and phenotyping were performed by DEPArray or fluorescence-activated cell sorting following enrichment and immunofluorescence staining (ALK/cytokeratins/CD45/Hoechst). CNA heterogeneity was evaluated in six ALK-rearranged patients harboring ≥ 10 CTCs/20 mL blood at resistance to 1

Identifiants

pubmed: 34272470
doi: 10.1038/s41698-021-00203-1
pii: 10.1038/s41698-021-00203-1
pmc: PMC8285416
doi:

Types de publication

Journal Article

Langues

eng

Pagination

67

Informations de copyright

© 2021. The Author(s).

Références

Clin Cancer Res. 2019 Nov 15;25(22):6671-6682
pubmed: 31439588
Cells. 2019 Sep 25;8(10):
pubmed: 31557946
Oncotarget. 2016 May 24;7(21):31014-28
pubmed: 27105536
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
N Engl J Med. 2013 Mar 21;368(12):1101-10
pubmed: 23514287
Cancer Res. 2017 May 1;77(9):2222-2230
pubmed: 28461563
Nature. 2020 Nov;587(7832):126-132
pubmed: 32879494
Clin Chem Lab Med. 2018 May 24;56(6):980-989
pubmed: 29397019
Br J Cancer. 2011 Oct 25;105(9):1338-41
pubmed: 21970878
Nat Med. 2017 Jan;23(1):114-119
pubmed: 27869802
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
EMBO Mol Med. 2014 Oct 30;6(11):1371-86
pubmed: 25358515
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Clin Cancer Res. 2012 Nov 15;18(22):6219-26
pubmed: 22843788
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Cancer Discov. 2014 Jun;4(6):662-673
pubmed: 24675041
Nat Genet. 2018 Aug;50(8):1189-1195
pubmed: 30013179
Int J Cancer. 2011 Oct 1;129(7):1651-60
pubmed: 21128227
Oncogene. 2013 Nov 21;32(47):5377-87
pubmed: 23934192
Cancer Discov. 2014 Feb;4(2):175-185
pubmed: 24436049
Mol Cancer. 2018 Feb 19;17(1):52
pubmed: 29455675
Cancer Discov. 2018 Jun;8(6):714-729
pubmed: 29650534
Clin Cancer Res. 2020 Jan 1;26(1):242-255
pubmed: 31585938
Nat Rev Genet. 2012 Jan 24;13(3):189-203
pubmed: 22269907
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40
pubmed: 21502504
Genome Res. 2017 Aug;27(8):1312-1322
pubmed: 28487279
Nat Rev Cancer. 2017 Oct 25;17(11):637-658
pubmed: 29068003
Bioinformatics. 2012 Feb 1;28(3):423-5
pubmed: 22155870
J Thorac Oncol. 2012 Feb;7(2):306-15
pubmed: 22173704
Int J Mol Sci. 2020 Jul 12;21(14):
pubmed: 32664698
Lancet Oncol. 2016 Dec;17(12):1683-1696
pubmed: 27836716
Biomed Pharmacother. 2009 Jul;63(6):396-403
pubmed: 18848758
Clin Cancer Res. 2012 Mar 1;18(5):1472-82
pubmed: 22235099
Nat Genet. 2020 Mar;52(3):283-293
pubmed: 32139907
Nat Rev Clin Oncol. 2018 Mar;15(3):139-150
pubmed: 29297505
Nat Rev Clin Oncol. 2014 Mar;11(3):129-44
pubmed: 24445517
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
J Biol Chem. 2013 Oct 18;288(42):30075-30086
pubmed: 23990466
Clin Cancer Res. 2018 Jun 15;24(12):2758-2770
pubmed: 29599410
Mol Oncol. 2016 Oct;10(8):1330-43
pubmed: 27491860
Ann Oncol. 2015 Jul;26(7):1408-15
pubmed: 25846554
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Cancer Res. 2018 Feb 15;78(4):1110-1122
pubmed: 29233927
J Clin Oncol. 2011 Apr 20;29(12):1556-63
pubmed: 21422424
Br J Cancer. 2011 Sep 6;105(6):847-53
pubmed: 21829190
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Nat Med. 2019 Oct;25(10):1534-1539
pubmed: 31591595
J Clin Oncol. 2013 Jun 20;31(18):2273-81
pubmed: 23669222
Clin Cancer Res. 2013 Jan 1;19(1):279-90
pubmed: 23091115
J Thorac Oncol. 2013 Apr;8(4):415-22
pubmed: 23344087
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Clin Cancer Res. 2018 Jul 15;24(14):3334-3347
pubmed: 29636358
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378

Auteurs

Marianne Oulhen (M)

Gustave Roussy, Université Paris-Saclay, "Rare Circulating Cells" Translational Platform, CNRS UMS3655 - INSERM US23 AMMICA, VILLEJUIF, France.
INSERM, U981 "Identification of Molecular Predictors and new Targets for Cancer Treatment", VILLEJUIF, France.

Patrycja Pawlikowska (P)

Gustave Roussy, Université Paris-Saclay, "Rare Circulating Cells" Translational Platform, CNRS UMS3655 - INSERM US23 AMMICA, VILLEJUIF, France.
INSERM, U981 "Identification of Molecular Predictors and new Targets for Cancer Treatment", VILLEJUIF, France.

Tala Tayoun (T)

Gustave Roussy, Université Paris-Saclay, "Rare Circulating Cells" Translational Platform, CNRS UMS3655 - INSERM US23 AMMICA, VILLEJUIF, France.
INSERM, U981 "Identification of Molecular Predictors and new Targets for Cancer Treatment", VILLEJUIF, France.
Univ Paris Sud, Université Paris-Saclay, Faculty of Medicine, LE KREMLIN-BICETRE, France.

Marianna Garonzi (M)

Menarini Silicon Biosystems S.p.A, BOLOGNA, Italy.

Genny Buson (G)

Menarini Silicon Biosystems S.p.A, BOLOGNA, Italy.

Claudio Forcato (C)

Menarini Silicon Biosystems S.p.A, BOLOGNA, Italy.

Nicolò Manaresi (N)

Menarini Silicon Biosystems S.p.A, BOLOGNA, Italy.

Agathe Aberlenc (A)

Gustave Roussy, Université Paris-Saclay, "Rare Circulating Cells" Translational Platform, CNRS UMS3655 - INSERM US23 AMMICA, VILLEJUIF, France.
INSERM, U981 "Identification of Molecular Predictors and new Targets for Cancer Treatment", VILLEJUIF, France.

Laura Mezquita (L)

Gustave Roussy, Université Paris-Saclay, Department of Medicine, VILLEJUIF, France.

Yann Lecluse (Y)

Gustave Roussy, Université Paris-Saclay, "Flow cytometry and Imaging" Platform, CNRS UMS3655 - INSERM US23AMMICA, VILLEJUIF, France.

Pernelle Lavaud (P)

Gustave Roussy, Université Paris-Saclay, Department of Medicine, VILLEJUIF, France.

Charles Naltet (C)

Gustave Roussy, Université Paris-Saclay, Department of Medicine, VILLEJUIF, France.

David Planchard (D)

Gustave Roussy, Université Paris-Saclay, Department of Medicine, VILLEJUIF, France.

Benjamin Besse (B)

Univ Paris Sud, Université Paris-Saclay, Faculty of Medicine, LE KREMLIN-BICETRE, France.
Gustave Roussy, Université Paris-Saclay, Department of Medicine, VILLEJUIF, France.

Françoise Farace (F)

Gustave Roussy, Université Paris-Saclay, "Rare Circulating Cells" Translational Platform, CNRS UMS3655 - INSERM US23 AMMICA, VILLEJUIF, France. francoise.farace@gustaveroussy.fr.
INSERM, U981 "Identification of Molecular Predictors and new Targets for Cancer Treatment", VILLEJUIF, France. francoise.farace@gustaveroussy.fr.
Univ Paris Sud, Université Paris-Saclay, Faculty of Medicine, LE KREMLIN-BICETRE, France. francoise.farace@gustaveroussy.fr.

Classifications MeSH